Méthotrexate And NotU. Müller-Ladner
List of bibliographic references
Number of relevant bibliographic references: 3.Ident. | Authors (with country if any) | Title |
---|---|---|
002623 | B. Le Goff [France, Australie] ; J.-M. Berthelot [France] ; Y. Maugars [France] ; E. Romas [Australie] | Alternative Use of Bisphosphonate Therapy for Rheumatic Disease |
005727 | J. A. O'Shaughnessy [États-Unis] ; J. Blum [États-Unis] ; V. Moiseyenko [Russie] ; S. E. Jones [États-Unis] ; D. Miles [Royaume-Uni] ; D. Bell [Australie] ; R. Rosso [Italie] ; L. Mauriac [France] ; B. Osterwalder [Suisse] ; H.-U. Burger [Suisse] ; S. Laws [France] | Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer |
006A47 | J. H. Schornagel [Australie, France] ; F. Cognetti ; J. B. Vermorken ; P. Cappelaere ; J. P. Armand ; J. Wildiers ; A. De Graeff ; M. Clavel ; T. Sahmoud ; J. Verweij ; P. H. M. De Mulder ; A. Kirkpatrick ; J. L. Lefebvre | Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck : a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study |
![]() | This area was generated with Dilib version V0.6.33. | ![]() |